[Insulin monotherapy in patients with diabetes mellitus type 2 developing secondary resistance to sulfanilamide preparations].
Patients with type-II diabetes mellitus differ widely in degrees of beta-cell functional activity, with some of them requiring insulinization as a corrective measure for hyperglycemia. It is a well-chosen and a propitious treatment option in those patients presenting with secondary resistance to sulfa drugs.
Gendeleka
G F
GF
D000328:Adult; D001835:Body Weight / Q000187:drug effects; D003920:Diabetes Mellitus / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004351:Drug Resistance; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D009765:Obesity; D013453:Sulfonylurea Compounds / Q000494:pharmacology / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds
Monoterapiia insulinom bol'nykh sakharnym diabetom II tipa pri razvitii vtorichnoĭ rezistentnosti k sul'fanilamidnym preparatam.